Literature DB >> 16940417

Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH).

Norimitsu Inoue1, Tomohisa Izui-Sarumaru, Yoshiko Murakami, Yuichi Endo, Jun-Ichi Nishimura, Ken Kurokawa, Maki Kuwayama, Hiroaki Shime, Takashi Machii, Yuzuru Kanakura, Gabrielle Meyers, Carl Wittwer, Zhong Chen, William Babcock, Debra Frei-Lahr, Charles J Parker, Taroh Kinoshita.   

Abstract

Somatic mutation of PIGA in hematopoietic stem cells causes deficiency of glycosyl phosphatidylinositol-anchored proteins in paroxysmal nocturnal hemoglobinuria (PNH) that underlies the intravascular hemolysis but does not account for expansion of the PNH clone. Immune mechanisms may mediate clonal selection but appear insufficient to account for the clonal dominance necessary for PNH to become clinically apparent. Herein, we report 2 patients with PNH whose PIGA-mutant cells had a concurrent, acquired rearrangement of chromosome 12. In both cases, der(12) had a break within the 3' untranslated region of HMGA2, the architectural transcription factor gene deregulated in many benign mesenchymal tumors, that caused ectopic expression of HMGA2 in the bone marrow. These observations suggest that aberrant HMGA2 expression, in concert with mutant PIGA, accounts for clonal hematopoiesis in these 2 patients and suggest the concept of PNH as a benign tumor of the bone marrow.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940417      PMCID: PMC1895453          DOI: 10.1182/blood-2006-05-025148

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

Review 1.  Molecular genetics of benign tumors.

Authors:  Jay L Hess; Plamen Kossev
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

Review 2.  Molecular genetics of paroxysmal nocturnal hemoglobinuria.

Authors:  Norimitsu Inoue; Yoshiko Murakami; Taroh Kinoshita
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

3.  Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia.

Authors:  Chiharu Sugimori; Tatsuya Chuhjo; Xingmin Feng; Hirohito Yamazaki; Akiyoshi Takami; Masanao Teramura; Hideaki Mizoguchi; Mitsuhiro Omine; Shinji Nakao
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

4.  The expression of HMGA genes is regulated by their 3'UTR.

Authors:  L Borrmann; S Wilkening; J Bullerdiek
Journal:  Oncogene       Date:  2001-07-27       Impact factor: 9.867

Review 5.  Role of the high mobility group A proteins in human lipomas.

Authors:  M Fedele; S Battista; G Manfioletti; C M Croce; V Giancotti; A Fusco
Journal:  Carcinogenesis       Date:  2001-10       Impact factor: 4.944

6.  Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway.

Authors:  G Baldassarre; M Fedele; S Battista; A Vecchione; A J Klein-Szanto; M Santoro; T A Waldmann; N Azimi; C M Croce; A Fusco
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

Review 7.  Molecular biology of HMGA proteins: hubs of nuclear function.

Authors:  R Reeves
Journal:  Gene       Date:  2001-10-17       Impact factor: 3.688

8.  HMGA2 is expressed in an allele-specific manner in human lipomas.

Authors:  Hena R Ashar; Alexei Tkachenko; Pritesh Shah; Kiran Chada
Journal:  Cancer Genet Cytogenet       Date:  2003-06

9.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.

Authors:  Norbert Frickhofen; Hermann Heimpel; Joachim P Kaltwasser; Hubert Schrezenmeier
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

10.  Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas.

Authors:  P Arlotta; A K Tai; G Manfioletti; C Clifford; G Jay; S J Ono
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

View more
  42 in total

1.  Gene therapy: Targeting β-thalassaemia.

Authors:  Derek A Persons
Journal:  Nature       Date:  2010-09-16       Impact factor: 49.962

2.  Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell.

Authors:  R Tominaga; T Katagiri; K Kataoka; K Kataoka; R K C Wee; A Maeda; H Gomyo; I Mizuno; T Murayama; S Ogawa; S Nakao
Journal:  Leukemia       Date:  2015-10-06       Impact factor: 11.528

Review 3.  New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.

Authors:  Tatsuya Kawaguchi; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

4.  The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells.

Authors:  Jeffrey J Pu; Rong Hu; Galina L Mukhina; Hetty E Carraway; Michael A McDevitt; Robert A Brodsky
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 5.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

Review 6.  Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria.

Authors:  Fahri Sahin; Melda Comert Ozkan; Nihal Gokmen Mete; Mumtaz Yilmaz; Nevin Oruc; Alev Gurgun; Meral Kayikcioglu; Ayse Guler; Figen Gokcay; Ferda Bilgir; Cengiz Ceylan; Oktay Bilgir; Ismail Hakan Sari; Guray Saydam
Journal:  Am J Blood Res       Date:  2015-06-15

Review 7.  Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2015-03-07       Impact factor: 3.722

Review 8.  Paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Amy E DeZern; Taroh Kinoshita; Robert A Brodsky
Journal:  Nat Rev Dis Primers       Date:  2017-05-18       Impact factor: 52.329

9.  On the dynamics of neutral mutations in a mathematical model for a homogeneous stem cell population.

Authors:  Arne Traulsen; Tom Lenaerts; Jorge M Pacheco; David Dingli
Journal:  J R Soc Interface       Date:  2012-12-05       Impact factor: 4.118

Review 10.  Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions.

Authors:  Aaron T Gerds; Bart L Scott
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.